This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Fortress Biotech (FBIO) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Fortress Biotech (FBIO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 44.70% and 0.49%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Phathom Pharmaceuticals (PHAT) delivered earnings and revenue surprises of -4.17% and 29.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
uniQure (QURE) delivered earnings and revenue surprises of 6.45% and 221%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Here Is Why Bargain Hunters Would Love Fast-paced Mover Fortress Biotech (FBIO)
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
AquaBounty Technologies, Inc. (AQB) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies (AQB) delivered earnings and revenue surprises of -7.75% and 4.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ovid Therapeutics (OVID) delivered earnings and revenue surprises of 26.09% and 40.95%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Aveanna Healthcare (AVAH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aveanna (AVAH) delivered earnings and revenue surprises of 40% and 1.16%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Myriad (MYGN) delivered earnings and revenue surprises of 20% and 1.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -10.53% and 23.98%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Fortress Biotech (FBIO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fulcrum Therapeutics, Inc. (FULC) delivered earnings and revenue surprises of -2.04% and 64.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 7.41% and 13.09%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Twist Bioscience (TWST) Surges 16.1%: Is This an Indication of Further Gains?
by Zacks Equity Research
Twist Bioscience (TWST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 2.13% and 5.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AquaBounty Technologies, Inc. (AQB) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
AquaBounty Technologies, Inc. (AQB) delivered earnings and revenue surprises of 20% and 23.18%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -20% and 17.35%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -18.75% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Fortress Biotech (FBIO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reata Pharmaceuticals, Inc. (RETA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Reata Pharmaceuticals, Inc. (RETA) delivered earnings and revenue surprises of -6.32% and 70.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -7.27% and 37.94%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 35.71% and 19.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma, Inc. (STRO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -6.33% and 48.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?